Experiences with Hepatitis C Treatment Access

This survey is seeking information about challenges accessing hepatitis C direct-acting antiviral treatment (e.g. Harvoni, Sovaldi, Viekira Pak, Zepatier, Olysio, Daklinza) through state Medicaid programs. This information will be used to inform the Centers for Medicare & Medicaid Services (CMS) about ongoing barriers to hepatitis C treatment access.

Note that patient names and contact information are not being collected. Please do not include that information in any of the comment fields. This survey is not intended to help with individual treatment access problems. Patients and providers are urged to contact the Patient Advocate Foundation’s Hepatitis C CareLine and Help-4-Hep to get individual assistance.

If you/your patient is having trouble accessing hepatitis C treatment through a payer other than Medicaid, please describe in the final comment field. This information will help inform advocacy efforts with all public and private payers.

For questions and more information about this survey, please contact Emily Stets at estets@nvhr.org.

* 1. What is today's date?

Date / Time
/
/

* 3. I am a ...

* 4. Please describe your (or your patient's or client’s) challenges accessing hepatitis C direct-acting antiviral medication through Medicaid.

* 5. If you (or your patient or client) have experienced challenges access hepatitis C direct-acting antiviral medication through other kinds of insurance, please describe that below.

T